$Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis$
Código QR

Código QR

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

IntroductionSeveral maintenance therapies are available for treatment of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). The objective of this review was to assess the efficacy and safety of lenalidomide monotherapy in these patients.MethodsMEDLINE, EMBASE, and the Coc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia Li, Jianpeng Zhou, Wei Guo, Xingtong Wang, Yangzhi Zhao, Ou Bai
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	diffuse large B-cell lymphoma lenalidomide monotherapy treatment outcome systematic review meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/948f2973e4f3437c8baa43709a547c33
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Absolute monocyte count as a prognostic parameter in diffuse large B cell lymphoma
por: IRIGOÍN,VICTORIA, et al.
Publicado: (2019)

Epstein-Barr Virus-Positive Adrenal Diffuse Large B-Cell Lymphoma after Treatment for Angioimmunoblastic T-Cell Lymphoma
por: Akiko Hashimoto, et al.
Publicado: (2021)

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
por: Jiao Cai, et al.
Publicado: (2021)

Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing
por: Fan Gao, et al.
Publicado: (2021)

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review
por: Bayarmagnai Weinstein, et al.
Publicado: (2021)

Therapy of Angiosarcoma with Thalidomide and Lenalidomide
por: M. Jules Mattes, et al.
Publicado: (2021)

Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature
por: Mengwei Ren, et al.
Publicado: (2021)

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review
por: Chao Chen, et al.
Publicado: (2021)

The Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment
por: Wei Wang, et al.
Publicado: (2021)

Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
por: Russell Sterrett, et al.
Publicado: (2021)

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
por: Schoenbeck KL, et al.
Publicado: (2020)

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
por: Schaefer A, et al.
Publicado: (2021)

Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England
por: Matthew James Smith, et al.
Publicado: (2021)

Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma
por: Alice Charwudzi, et al.
Publicado: (2021)

More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
por: Lucijanic M, et al.
Publicado: (2021)

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
por: Kanta Devi, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Hongmei Wang, et al.
Publicado: (2021)

Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma
por: Esther K. Elliott, et al.
Publicado: (2021)

Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
por: Johanne Marie Holst, et al.
Publicado: (2021)

Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
por: Sunkaraneni S, et al.
Publicado: (2017)

A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma
por: Luis F. Oñate-Ocaña, et al.
Publicado: (2021)

Antibody Therapies for Large B-Cell Lymphoma
por: Novo M, et al.
Publicado: (2021)

Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
por: Santos-Moreno P, et al.
Publicado: (2021)

The Value of Prognostic Nutritional Index (PNI) on Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: A Multicenter Retrospective Study of HHLWG Based on Propensity Score Matched Analysis
por: Shen Z, et al.
Publicado: (2021)

Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
por: Palacios-Campos,Adriana, et al.
Publicado: (2020)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Julio Delgado, et al.
Publicado: (2021)

Linfoma difuso de células grandes B rectal en un paciente con colitis ulcerosa
por: Quera,Rodrigo, et al.
Publicado: (2017)

Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
por: Orienti I, et al.
Publicado: (2020)

Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India
por: Ajay Gogia, et al.
Publicado: (2021)

Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation
por: Faison S, et al.
Publicado: (2020)

Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay
por: Oliver,Carolina, et al.
Publicado: (2013)

Case study-based systematic review of literature on lymphoma-associated cardiac tamponade
por: Mohammad Abrar Shareef, et al.
Publicado: (2021)

Linfoma de células grandes B originado en enfermedad de Castleman. Reporte de un caso y revisión de la literatura
por: Avilés-Salas,Alejandro, et al.
Publicado: (2017)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang F, et al.
Publicado: (2019)

Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
por: Dipenkumar Modi, et al.
Publicado: (2021)

Primary cutaneous CD 30 (+) ALK (-) anaplastic large cell lymphoma with dermoscopic findings: a case report
por: Tugba Kevser Ustunbas Uzuncakmak, et al.
Publicado: (2017)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Weiping Liu, et al.
Publicado: (2021)

ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma
por: Giulio Sartori, et al.
Publicado: (2021)

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Ebru Pekgüç, et al.
Publicado: (2021)

The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
por: Ka-Won Kang, et al.
Publicado: (2021)